Keros Therapeutics, Inc. (NASDAQ: KROS) has announced it will discontinue all development of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) after topline data from the TROPOS Phase 2 ...

Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

Former congressman Michael Burgess opposes a White House executive order that ties U.S. drug prices to the artificially low, ...

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

The president said that, because of his executive order, prescription drug prices would be cut “almost immediately.” Here's ...

With thousands of gene and cell therapies in the pipeline, health systems should make sure they are for these drugs, which can cost millions per dose, according to the American Society of ...

The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest ...

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Burkina Faso’s first vet drug plant is expected to save $17.3M yearly on imports. • The $36.4M factory will produce 110M doses and create over 600 jobs. • The project supports national food ...